A widely available over-the-counter nasal spray has shown remarkable potential in reducing COVID-19 infections, according to a new clinical trial. Researchers revealed that participants who used the spray regularly experienced two-thirds fewer COVID-19 cases compared to those who did not.
The trial, conducted across several healthcare centers, involved hundreds of volunteers who were monitored over a set period. Findings indicated that the spray worked as a protective barrier inside the nasal cavity, the primary entry point for the virus.
Lead investigators highlighted the accessibility of this treatment, emphasizing its affordability and ease of use compared to more complex preventive methods. One researcher noted, “This simple intervention could provide a significant layer of protection, especially for those in high-risk environments.”
Experts believe the spray may help reduce transmission rates in crowded spaces such as schools, offices, and public transport. While vaccines remain the most effective defense against severe illness, the nasal spray could act as an additional tool in preventing infections at the community level.
The team stressed that more studies are needed to confirm long-term effectiveness and to assess whether the spray can protect against emerging variants. However, they are optimistic that its widespread availability could make it a game-changer in global COVID-19 prevention strategies.
With the pandemic continuing to evolve, this breakthrough offers a promising glimpse of how everyday products could support public health and reduce the strain on healthcare systems worldwide.
Nasal Spray Shows 66% Drop in COVID Cases in Clinical Trial
